Overall Score

Pricing Power

Gross margin remains extremely high at 99.4%, but the company is still posting deeply negative operating and net margins, indicating no durable pricing power yet.

Revenue per share is only 0.66 while price-to-sales remains elevated at 35.5x, suggesting the market is still pricing in future commercialization rather than current moat strength.

Scale Advantages

The business is still pre-scale from a profitability standpoint, with asset turnover of 0.06 and negative operating cash flow, so there is little evidence of operating leverage.

Very high current ratio of 16.9x reflects a large cash buffer, but it does not yet translate into scale-based efficiency or cost advantage.

Switching Costs

No evidence of customer lock-in, recurring revenue, or installed-base retention effects is visible in the financials.

The company remains dependent on future product adoption rather than any demonstrated switching-cost moat.

Network Effects

There is no sign of a network-driven business model in the reported metrics.

The company’s economics are driven by R&D and clinical development, not by user growth or platform effects.

Intangible Assets

Heavy R&D spend at 4.6% of revenue suggests pipeline investment, but the financials do not yet show monetized intellectual-property advantage.

The gross margin profile implies product economics could be strong if commercialization succeeds, but that advantage is not yet proven as a moat.